Mesalazine-associated interstitial nephritis

Nephrology Dialysis Transplantation

Volumn 11, Issue 4, 1996, Pages 614-621

  World, M J ^a   Stevens, P E ^b   Ashton, M A ^c   Rainford, D J ^b  

^a Royal Army Medical College   (United Kingdom)

^b Prncs Mary's Roy AF Hospital   (Canada)

^c Royal Air Force Halton   (United Kingdom)

Author keywords

Inflammatory bowel disease; Interstitial nephritis; Lack of urinary abnormalities; Mesalazine (Asacol); Monitoring renal function

Indexed keywords

CREATININE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0029880550     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027349     Document Type: Article

References (34)

1. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 82-86
2. Riley SA, Mani V, Goodman MJ et al. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669-674
3. Riley SA, Mani V, Goodman MJ et al Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis relapse. Gastroenterology 1988; 94: 1381-1389
4. Dew MJ, Hughes P, Harries AD et al. Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid. Br Med J 1982; 285: 1012
5. Dew MJ, Hughes P, Harries AD et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 1983; 287: 23-24
6. Rutgeerts P. Comparative efficacy of coated oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989; 3: 183-191
7. Dew MJ, Harries AD, Evans BK, Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. Lancet 1983; 2: 801
8. Schroeder KW, Tremaine WJ, Ilstrup MS. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-1629
9. Austin CA, Cann PA, Jones TH, Holdsworth CD. Exacerbation of pain and diarrhoea in patients treated with 5-aminosalicylic acid therapy for ulcerative colitis Lancet 1984; 1: 917-918
10. Schwarz AG, Targan SR, Saxon A, Weinstein WM. Sulphasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982; 306: 409-412
11. Werlin SL, Grand RJ. Bloody diarrhoea - a new complication of sulphasalazine. J Pediatr 1978; 92: 450-451
12. Adler RD. Sulphasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982; 307: 315
13. Ruf-ballauf W, Hofstaedter F, Krentz K. Akute interstitielle Nephritis durch 5-Aminosalicylsaeure? Internist 1989; 30: 262-264
14. Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presentina as weight loss. Gut 1992; 33: 563-564
15. Mehta RP. Acute interstitial nephritis due to 5-aminosalicylic acid. Can Med Assoc 1990; 143: 1031-1032
16. von Muehlendahl KE. Nephritis durch 5-Aminosalicylsaeure. Dische Med Wochenschr 1989, 114: 236
17. Henning MV, Meinhold J, Eisenhauer T et al Chronische interstitielle Nephritis nach Behandlung mit 5-Aminosalicylsaeure. Dtsche Med Wochenschr 1989; 114: 1090-1091
18. Thutuvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-1496
19. Smilde TJ, van Liebergen FJHM, Koolen MI et al. Tubulo-interstitiele nefritis door mesalazine (5-ASA)-preparaten. Ned Tijdschr Geneeskd 1994; 138: 2557-2561
20. Daneshmend TK. Mesalazine-associated thrombocytopenia. Lancet 1991; 1: 1297-1298
21. Barbour VM, Williams PF. Nephrotic syndrome associated with sulphasalazine Br Med J 1990; 301: 818
22. McHenry PM, Allan JG, Rodger RSC, Lever RS. Nephrotoxicity due to azathioprine. Br J Dermatol 1993; 128: 106
23. Novis BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J 1988; 296: 1442
24. Behrens R, Ruder H. Chronische entzundliche Darmerkrankung und Nephritis. Klin Padiatr 1992; 204: 61-64
25. Arm JP, Rainford DJ, Turk EP. Acute renal failure and infectious mononucleosis. J Infect 1984; 9: 293-297
26. Anonymous. Nephrotoxicity associated with mesalazine (Asacol). Comminee on Safety of Medicines Current Problems No. 30, December 1990
27. Adams DH, Adu D. Non-steroidal anti-inflammatory drugs and the kidney. In: Cameron JS, Davison AM, Grunfeld J-P, Kerr D, Ritz E, Eds. Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford, 1992; 819-825
28. Diener U, Tuczek H-V, Fischer C et al. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn-Schmiedebergs Arch Pathology 1984; 326: 278-282
29. Tremaine WJ, Schroeder KW. Urinary sediment abnormalities in patients on long term oral 5-aminosalicyclic acid (5-ASA) for chronic ulcerative colitis. Gastroenterology 1988; 94: A465
30. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drua treatment. Gut 1982; 33: 1384-1352
31. Schroeder KW, Tremaine WJ. Oral 5-aminosalicylic acid (Asacol) for treatment of symptomatic ulcerative colitis. Gastroenterology 1986; 90: 1620
32. Cameron JS. Allergic interstitial nephritis: clinical features and pathogenesis. Q J Med 1988; 66: 97-115
33. Thomas DM, Nicholls AJ, Feest TG. Glomerulonephritis and ulcerative colitis, is there an association? Nephrol Dial Transplant 1990; 5: 628-629
34. Anonymous. Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis. Drug Ther Bull 1992; 30: 50-52